Bausch Health Companies Inc.announced it has initiated a clinical trial program in Canada evaluating an investigational use of Virazole (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19.